Sildenafil Treatment of Primary Pulmonary Hypertension | Zendy

Kevin B. Laupland | Zendy; Doug Helmersen | Zendy; David A. Zygun | Zendy; Sidney M Viner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sildenafil Treatment of Primary Pulmonary Hypertension

Author(s) -

Kevin B. Laupland,

Doug Helmersen,

David A. Zygun,

Sidney M Viner

Publication year - 2003

Publication title -

canadian respiratory journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.675

H-Index - 53

eISSN - 1916-7245

pISSN - 1198-2241

DOI - 10.1155/2003/612905

Subject(s) - medicine , sildenafil , pulmonary hypertension , vasodilator agents , cardiology , vasodilation

A 37-year-old woman with primary pulmonary hypertension and worsening symptomatology underwent pulmonary artery (PA) catheterization and vasodilator trials. Oxygen had no effect, but 10 parts/million of nitric oxide reduced mean PA (PAm) pressure by 20%. Prostacyclin infusion at 8 ng/kg/min decreased the PAm pressure by 11%, but further dose increases were limited by systemic hypotension. Sildenafil in doses of 25 mg or higher resulted in an average decrease of 14% in PAm pressure. Sildenafil is a potentially useful treatment option for patients with primary pulmonary hypertension, and further investigation is warranted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research